Muraille E, De Smedt T, Andris F, Pajak B, Armant M, Urbain J, Moser M, Leo O
Department of Molecular Biology, Free University of Brussels, Belgium.
J Immunol. 1997 Mar 15;158(6):2638-47.
Staphylococcal enterotoxin B (SEB) is a bacterial enterotoxin able to simultaneously bind to class II molecules on APCs and to selected V beta regions (including V beta 8) of the TCR complex. Administration of SEB to adult BALB/c mice results in clonal activation of T cells bearing V beta 8 receptors, leading to an excessive release of proinflammatory cytokines. This initial immune response is followed by a long-lasting state of V beta 8-specific unresponsiveness, thought to benefit both the host (as it contributes to the down-regulation of the inflammatory response) and the bacterium (through ligand-specific T cell anergy). However, it is not clear how this type of restricted unresponsiveness can effectively impair the generation of an antibacterial response. To gain insight into the mechanism by which Gram-positive bacteria subvert the host immune response, we have investigated the immune competence of SEB-treated mice 48 h following SEB administration. We demonstrate in this report that in vivo, SEB induces a transient but profound state of unresponsiveness affecting both T and Ag-presenting cell functions. Although in vivo activation by SEB appears to be V beta-restricted under our experimental conditions, SEB-treated mice displayed an early (lasting 48 to 72 h postinjection) and V beta-unrestricted unresponsive state characterized by the inability to produce IL-2 in response to polyclonal TCR mitogens including third party bacterial superantigens (staphylococcal enterotoxin A and toxic shock syndrome toxin 1, SEA and TSST-1, respectively), Abs to non-SEB reactive V beta regions (V beta 6), anti-CD3 epsilon Abs, and a lectin (Con A). Spleen cell populations from SEB-treated mice also displayed defective APC functions, possibly related to a selective decrease in splenic dendritic cells numbers. Taken together, these observations indicate that SEB induces an early and transient state of immunodeficiency in vivo, representing a potential mechanism for escaping host immune surveillance.
葡萄球菌肠毒素B(SEB)是一种细菌肠毒素,能够同时与抗原呈递细胞(APC)上的II类分子以及T细胞受体复合物的特定Vβ区域(包括Vβ8)结合。给成年BALB/c小鼠注射SEB会导致携带Vβ8受体的T细胞发生克隆性激活,从而导致促炎细胞因子过度释放。这种初始免疫反应之后会出现Vβ8特异性无反应的持久状态,人们认为这对宿主(因为它有助于炎症反应的下调)和细菌(通过配体特异性T细胞无反应性)都有益。然而,尚不清楚这种类型的受限无反应性如何有效地损害抗菌反应的产生。为了深入了解革兰氏阳性菌颠覆宿主免疫反应的机制,我们研究了注射SEB后48小时SEB处理小鼠的免疫能力。我们在本报告中证明,在体内,SEB会诱导一种短暂但深刻的无反应状态,影响T细胞和抗原呈递细胞的功能。尽管在我们的实验条件下,SEB在体内的激活似乎受Vβ限制,但SEB处理的小鼠表现出一种早期(注射后持续48至72小时)且不受Vβ限制的无反应状态,其特征是无法对包括第三方细菌超抗原(分别为葡萄球菌肠毒素A和中毒性休克综合征毒素1,即SEA和TSST-1)、针对非SEB反应性Vβ区域(Vβ6)的抗体、抗CD3ε抗体和一种凝集素(伴刀豆球蛋白A)在内的多克隆TCR有丝分裂原产生白细胞介素-2。来自SEB处理小鼠的脾细胞群体也表现出有缺陷的APC功能,这可能与脾树突状细胞数量的选择性减少有关。综上所述,这些观察结果表明,SEB在体内诱导了一种早期且短暂的免疫缺陷状态,这代表了逃避宿主免疫监视的一种潜在机制。